New Investing App Saves Investors an Average of $97,347
Most people are terrible at buying and selling stocks at the right time, but the TradeSmith app takes the emotion out of investing.

Our back test shows, the average investor would've made $97,347 more just by using the TradeSmith app analyzer software.

Check out this FREE video.
>>>

MXCT Insider Trading (MaxCyte)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): £222,400
Insider Selling (Last 12 Months): GBX 0

MaxCyte Insider Trading History Chart

This chart shows the insider buying and selling history at MaxCyte by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

MaxCyte Share Price & Price History

Current Price: GBX 371
Price Change: Price Decrease of -39 (-9.51%)
As of 06/30/2022 05:00 PM ET

This chart shows the closing price history over time for MXCT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.
Download your FREE Options Strategy Guide Today.

MaxCyte Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/22/2021Richard DouglasInsiderBuy20,000GBX 1,112£222,400
2/18/2021Will BrookeInsiderSell40,900GBX 1,015£415,135
2/3/2021Stark ThompsonInsiderSell30,000GBX 700£210,000
10/1/2020Stark ThompsonInsiderSell25,000GBX 355£88,750
See Full Table
Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.
Download your FREE Options Strategy Guide Today.

SEC Filings (Institutional Ownership Changes) for MaxCyte (LON:MXCT)

MaxCyte logo
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Read More on MaxCyte

Today's Range

Now: GBX 371
Low: 371
High: 405

50 Day Range

MA: GBX 376.25
Low: 292
High: 450

52 Week Range

Now: GBX 371
Low: 280
High: 1,235

Volume

7,144 shs

Average Volume

71,361 shs

Market Capitalization

£376.71 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of MaxCyte?

MaxCyte's top insider investors include:
  1. Richard Douglas (Insider)
  2. Stark Thompson (Insider)
  3. Will Brooke (Insider)
Learn More about top insider investors at MaxCyte.
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!

When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Get in on the action here.